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ABSTRACT
We have performed exome-wide association studies to identify genetic variants 
that influence body mass index or confer susceptibility to obesity or metabolic 
syndrome in Japanese. The exome-wide association study for body mass index 
included 12,890 subjects, and those for obesity and metabolic syndrome included 
12,968 subjects (3954 individuals with obesity, 9014 controls) and 6817 subjects 
(3998 individuals with MetS, 2819 controls), respectively. Exome-wide association 
studies were performed with Illumina HumanExome-12 DNA Analysis BeadChip or 
Infinium Exome-24 BeadChip arrays. The relation of genotypes of single nucleotide 
polymorphisms to body mass index was examined by linear regression analysis, 
and that of allele frequencies of single nucleotide polymorphisms to obesity or 
metabolic syndrome was evaluated with Fisher’s exact test. The exome-wide 
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association studies identified six, 11, and 40 single nucleotide polymorphisms as 
being significantly associated with body mass index, obesity (P <1.21 × 10–6), 
or metabolic syndrome (P <1.20 × 10–6), respectively. Subsequent multivariable 
logistic regression analysis with adjustment for age and sex revealed that three 
and five single nucleotide polymorphisms were related (P < 0.05) to obesity or 
metabolic syndrome, respectively, with one of these latter polymorphisms—
rs7350481 (C/T) at chromosome 11q23.3—also being significantly (P < 3.13 × 
10–4) associated with metabolic syndrome. The polymorphism rs7350481 may thus 
be a novel susceptibility locus for metabolic syndrome in Japanese. In addition, 
single nucleotide polymorphisms in three genes (CROT, TSC1, RIN3) and at four loci 
(ANKK1, ZNF804B, CSRNP3, 17p11.2) were implicated as candidate determinants 
of obesity and metabolic syndrome, respectively.
INTRODUCTION
Obesity is a major risk factor for coronary artery 
disease, hypertension, diabetes mellitus, dyslipidemia, 
and several types of cancer [1, 2]. Epidemiological studies 
in different populations have recognized a contribution 
of genetic factors to individual susceptibility to obesity 
[1, 3], with the heritability of this condition having been 
estimated at 40% to 70% [4]. Genome-wide association 
studies (GWASs) and meta-analyses of such studies—
most performed with individuals of European descent [5–
14] or in East Asian populations [15–17]—have identified 
>100 loci or genes that influence body mass index (BMI) 
or confer susceptibility to obesity or adiposity.
Metabolic syndrome (MetS) is also a crucial risk 
factor for cardiovascular disease, diabetes mellitus [18, 
19], and cancer [20, 21]. The heritability of MetS has been 
estimated to be ~30% [22, 23]. GWASs have implicated 
various loci or genes in predisposition to MetS or to traits 
of this syndrome in individuals of European [22, 23] or 
African [24] ancestry or in Asian Indians [25].
Genetic variants identified in previous GWASs 
typically have a minor allele frequency (MAF) of ≥5% 
and a small individual effect size. Given that these 
common variants explain only a fraction of the heritability, 
it is expected that low-frequency (0.5% ≤ MAF < 5%) 
or rare (MAF < 0.5%) variants with larger effect sizes 
also contribute to the genetic architecture of obesity or 
MetS [26]. Although several polymorphisms have been 
found to be significantly associated with BMI in East 
Asian populations [15–17], genetic variants, including 
low-frequency and rare variants, that influence BMI or 
contribute to predisposition to obesity or MetS in Japanese 
remain to be identified definitively.
We have now performed exome-wide association 
studies (EWASs) with the use of exome array–based 
genotyping methods to identify SNPs—in particular, low-
frequency or rare coding variants with moderate to large 
effect sizes—that influence BMI or confer susceptibility 
to obesity or MetS in the Japanese population. We used 
Illumina arrays that provide coverage of functional 
single nucleotide polymorphisms (SNPs) in entire exons 
including low-frequency and rare variants.
RESULTS
EWAS for BMI
We examined the relation of genotypes of 41,327 
SNPs that passed quality control to BMI in 12,890 
subjects by linear regression analysis. A Manhattan plot 
of the EWAS is shown in Supplementary Figure 1A. After 
Bonferroni’s correction, six SNPs were significantly [P < 
1.21 × 10–6 (0.05/41,327)] associated with BMI (Table 1).
EWAS for obesity
We performed an EWAS for obesity with 12,968 
subjects [3954 individuals with obesity (BMI of ≥25 kg/
m2), 9014 controls (BMI of <25 kg/m2)], the characteristics 
of whom are shown in Table 2. The frequency of men and 
the prevalence of smoking, hypertension, diabetes mellitus, 
dyslipidemia, and hyperuricemia as well as BMI, waist 
circumference, systolic and diastolic blood pressure, fasting 
plasma glucose level, blood glycosylated hemoglobin 
(hemoglobin A1c) content, and the serum concentrations of 
triglycerides, low density lipoprotein (LDL)–cholesterol, 
and uric acid were greater, whereas age and the serum 
concentration of high density lipoprotein (HDL)-cholesterol 
were lower, in subjects with obesity than in controls.
We examined the relation of allele frequencies 
of 41,327 SNPs to obesity with Fisher’s exact test. A 
Manhattan plot for the EWAS is shown in Supplementary 
Figure 1B. After Bonferroni’s correction, 11 SNPs were 
significantly (P < 1.21 × 10–6) associated with obesity 
(Table 3). The genotype distributions of these SNPs were 
in Hardy-Weinberg equilibrium (P > 0.001) among both 
subjects with obesity and controls (Supplementary Table 1).
The relation of the 11 SNPs to obesity was further 
examined by multivariable logistic regression analysis 
with adjustment for age and sex (Supplementary Table 
2). Three SNPs [rs7808249 (G/A) of CROT, rs1076160 
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(A/G) of TSC1, rs8018360 (C/T) of RIN3] were related 
(P < 0.05 in at least one genetic model) to obesity, 
although there was no SNP significantly [P < 0.0011 
(0.05/44)] associated with this condition (Table 4). The 
minor A and T alleles of rs7808249 and rs8018360, 
respectively, were risk factors for obesity, whereas the 
minor G allele of rs1076160 was protective against this 
condition.
Relation of nine SNPs to BMI
We examined the relation of genotypes for nine 
SNPs to BMI by one-way analysis of variance (ANOVA). 
The six SNPs (rs633715, rs543874, rs1421085, rs1558902, 
rs8050136, rs9939609) identified in the EWAS of BMI 
were all significantly [P < 0.0056 (0.05/9)] associated 
with BMI. Among the three SNPs found to be related to 
Table 2: Characteristics of the 12,968 subjects in the EWAS of obesity
Characteristic Obesity Controls P
No. of subjects 3954 9014 9014
Age (years) 59.3 ± 12.5 60.8 ± 13.6 <0.0001
Sex (male/female, %) 62.2/37.8 54.3/45.7 <0.0001
BMI (kg/m2) 27.2 ± 2.7 21.5 ± 2.1 <0.0001
Waist circumference (cm) 90.3 ± 7.1 77.2 ± 6.2 <0.0001
Current or former smoker (%) 41.0 34.1 <0.0001
Hypertension (%) 64.4 47.9 <0.0001
Systolic blood pressure (mmHg) 135 ± 23 129 ± 24 <0.0001
Diastolic blood pressure (mmHg) 79 ± 13 75 ± 13 <0.0001
Diabetes mellitus (%) 30.5 20.1 <0.0001
Fasting plasma glucose (mmol/L) 6.49 ± 2.56 6.09 ± 2.35 <0.0001
Blood hemoglobin A1c (%) 6.15 ± 1.28 5.80 ± 1.11 <0.0001
Dyslipidemia (%) 75.2 57.5 <0.0001
Serum triglycerides (mmol/L) 1.70 ± 1.14 1.35 ± 0.95 <0.0001
Serum HDL-cholesterol (mmol/L) 1.37 ± 0.38 1.58 ± 0.47 <0.0001
Serum LDL-cholesterol (mmol/L) 3.22 ± 0.87 3.07 ± 0.83 <0.0001
Chronic kidney disease (%) 25.0 23.2 0.0312
Serum creatinine (µmol/L) 77.6 ± 72.6 78.8 ± 87.6 0.4543
Estimated GFR (mL min–1 1.73 m–2) 71.8 ± 18.7 72.5 ± 21.2 0.0510
Hyperuricemia (%) 23.7 15.6 <0.0001
Serum uric acid (µmol/L) 348 ± 93 319 ± 94 <0.0001
Quantitative data are means ± SD and were compared between subjects with obesity and controls with the unpaired 
Student’s t test. Categorical data were compared between the two groups with Fisher’s exact test. Based on Bonferroni’s 
correction, a P value of <0.0025 (0.05/20) was considered statistically significant. GFR, glomerular filtration rate.
Table 1: The six SNPs significantly (P < 1.21 × 10–6) associated with BMI in the EWAS
Gene dbSNP Nucleotide (amino acid) substitutiona Chromosome: position MAF (%) P (genotype)
rs633715 T/C 1: 177883445 22.0 8.33 × 10–8
rs543874 A/G 1: 177920345 21.9 1.36 × 10–7
FTO rs1421085 T/C 16: 53767042 19.1 5.37 × 10–7
FTO rs1558902 T/A 16: 53769662 19.1 6.67 × 10–7
FTO rs8050136 C/A 16: 53782363 19.2 1.08 × 10–6
FTO rs9939609 T/A 16: 53786615 19.3 1.13 × 10–6
The relation of genotypes of SNPs to BMI was evaluated by linear regression analysis. aMajor allele/minor allele.
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obesity, rs7808249 and rs1076160 were related (P < 0.05) 
to BMI, whereas rs8018360 was not (Table 5).
EWAS for MetS
We performed an EWAS of MetS with 6817 subjects 
[3998 individuals with MetS (three or more of the five 
components of MetS), 2819 controls (none of the five 
components of MetS)], the characteristics of whom are 
shown in Table 6. Age, the frequency of men, BMI, waist 
circumference, systolic and diastolic blood pressure, 
fasting plasma glucose level, blood hemoglobin A1c 
content, and the serum concentrations of triglycerides, 
LDL-cholesterol, creatinine, and uric acid were greater, 
whereas the serum concentration of HDL-cholesterol and 
estimated glomerular filtration rate were lower, in subjects 
with MetS than in controls.
We examined the relation of allele frequencies of 
41,675 SNPs that passed quality control to MetS with 
Fisher’s exact test. A Manhattan plot of the EWAS is 
shown in Supplementary Figure 1C. After Bonferroni’s 
correction, 40 SNPs were significantly [P < 1.20 × 10–6 
(0.05/41,675)] associated with MetS (Table 7). The 
genotype distributions of these SNPs were in Hardy-
Weinberg equilibrium (P > 0.001) among both subjects 
with MetS and controls (Supplementary Table 3).
The relation of the 40 SNPs to MetS was further 
examined by multivariable logistic regression analysis 
with adjustment for age and sex (Supplementary Table 
4). Five SNPs (rs1800497, rs1406503, rs1007732, 
rs56150213, rs7350481) were related (P < 0.05 in at 
least one genetic model) to MetS. Among these SNPs, 
rs7350481 (C/T) at chromosomal region 11q23.3 was also 
significantly [P < 3.13 × 10-4 (0.05/160)] associated with 
Table 3: The 11 SNPs significantly (P < 1.21 × 10–6) associated with obesity in the EWAS
Gene dbSNP Nucleotide (amino acid) substitutiona
Chromosome: 
position
MAF (%) P (genotype) AlleleOR
TRIM36 rs3749745 G/C (E725Q) 5: 115126517 1.9 5.01 × 10–38 0.88
PDIA5 rs2292661 C/T (T391M) 3: 123150263 0.7 2.05 × 10–35 0.95
OR10P1 rs7970885 G/A (V200M) 12: 55637489 19.0 6.82 × 10–14 1.01
CROT rs7808249 G/A 7: 87354399 32.0 1.30 × 10–12 1.06
rs2068204 C/T 6: 33090941 37.1 5.02 × 10–11 1.02
DAW1 rs10191097 T/G 2: 227911955 29.1 7.17 × 10–11 0.98
TRIM40 rs757259 G/A (E244K) 6: 30147765 16.0 7.21 × 10–11 0.98
TSC1 rs1076160 A/G 9: 132900647 45.9 4.89 × 10–10 0.95
RIN3 rs8018360 C/T 14: 92521014 19.9 6.79 × 10–9 1.04
HYOU1 rs144079825 G/C (E258Q) 11: 119054143 0.1 3.96 × 10–7 0.98
ECE2 rs145491613 A/G (N388S) 3: 184278550 0.4 9.91 × 10–7 0.69
Allele frequencies were analyzed with Fisher’s exact test. aMajor allele/minor allele. OR, odds ratio.
Table 4: Relation of SNPs to obesity as determined by multivariable logistic regression analysis
SNP
Dominant Recessive Additive 1 Additive 2
P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI)
rs7808249 G/A 0.0241 1.09 (1.01–1.18) 0.5172 0.0307
1.09 (1.01–
1.18) 0.2039
rs1076160 A/G 0.2661 0.0340 0.90 (0.82–0.99) 0.6676 0.0410
0.89 (0.80–
0.99)
rs8018360 C/T 0.6700 0.0339 1.23 (1.02–1.47) 0.8658 0.0378
1.22 (1.01–
1.47)
Multivariable logistic regression analysis was performed with adjustment for age and sex. Based on Bonferroni’s correction, 
a P value of <0.0011 (0.05/44) was considered statistically significant. OR, odds ratio; CI, confidence interval.
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MetS, with the minor T allele being a risk factor for this 
condition (Table 8).
Relation of five SNPs to components of MetS
We examined the relation of the five identified SNPs 
to the components of MetS—waist circumference, serum 
concentrations of triglycerides and HDL-cholesterol, 
blood pressure, and fasting plasma glucose level—in the 
6817 subjects by one-way ANOVA (Table 9). The SNP 
rs7350481 (C/T) was significantly [P < 0.0013 (0.05/40)] 
associated with the serum concentrations of triglycerides 
and HDL-cholesterol (for men), whereas the other four 
SNPs were not associated with any of these parameters.
Relation of SNPs identified in the present study 
to phenotypes examined in previous GWASs
We examined the genes, chromosomal loci, and 
SNPs identified in the present study to obesity- or MetS-
related phenotypes previously investigated in GWASs 
deposited in a public database [GWAS Catalog (http://
www.ebi.ac.uk/gwas)]. In the case of our BMI and obesity 
studies, chromosomal region 1q25 was previously shown 
to be related to BMI [7, 8, 12], obesity [7], and body fat 
percentage [14], whereas FTO was previously identified as 
a genetic determinant of BMI [6, 12, 27], obesity [7, 28], 
body fat percentage [14], adiposity [29], and circulating 
leptin level [30]. The remaining three genes (CROT, TSC1, 
RIN3) have not been previously associated with BMI or 
obesity (Supplementary Table 5). In the case of our MetS 
study, the five identified genes or loci (ANKK1, ZNF804B, 
CSRNP3, 17p11.2, 11q23.3) have not been previously 
identified as susceptibility loci for MetS, although 
ZNF804B and chromosomal region 11q23.3 were found to 
be related to BMI in women [31] or serum concentrations 
of triglycerides and HDL-cholesterol [32, 33], respectively 
(Supplementary Table 5).
DISCUSSION
We have now shown that two SNPs [rs633715 
(T/C), rs543874 (A/G)] at chromosomal region 1q25 and 
four SNPs [rs1421085 (T/C), rs1558902 (T/A), rs8050136 
Table 5: Relation of SNPs identified in the present study to BMI
SNP BMI (kg/m2) P
Associated with BMI
rs633715 T/C TT TC CC
23.1 ± 3.4 23.5 ± 3.6 23.5 ± 3.6 5.38 × 10–8
rs543874 A/G AA AG GG
23.1 ± 3.4 23.5 ± 3.5 23.5 ± 3.6 9.52 × 10–8
rs1421085 T/C TT TC CC
23.2 ± 3.4 23.4 ± 3.5 23.7 ± 3.8 3.49 × 10–6
rs1558902 T/A TT TA AA
23.2 ± 3.4 23.4 ± 3.5 23.7 ± 3.8 4.28 × 10–6
rs8050136 C/A CC CA AA
23.2 ± 3.4 23.4 ± 3.5 23.7 ± 3.8 6.85 × 10–6
rs9939609 T/A TT TA AA
23.2 ± 3.4 23.4 ± 3.5 23.7 ± 3.8 7.16 × 10–6
Associated with obesity
rs7808249 G/A GG GA AA
23.2 ± 3.4 23.3 ± 3.5 23.3 ± 3.5 0.0266
rs1076160 A/G AA AG GG
23.3 ± 3.5 23.3 ± 3.5 23.1 ± 3.4 0.0424
rs8018360 C/T CC CT TT
23.3 ± 3.4 23.2 ± 3.5 23.4 ± 3.4 0.6303
Data were compared among genotypes by one-way ANOVA. Based on Bonferroni’s correction, P values of <0.0056 
(0.05/9) were considered statistically significant and are shown in bold.
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(C/A), rs9939609 (T/A)] of FTO were significantly 
associated with BMI. Chromosomal region 1q25 and FTO 
were previously identified as susceptibility loci for BMI 
and obesity [6–8, 12, 27, 28]. We have also identified 
three obesity-related genes (CROT, TSC1, RIN3) that have 
not previously been implicated as determinants of BMI 
or obesity. In addition, we identified rs7350481 (C/T) at 
11q23.3 as a new susceptibility locus for MetS, with SNPs 
in ANKK1, ZNF804B, and CSRNP3 as well as at 17p11.2 
also being implicated as candidate susceptibility loci for 
MetS.
SNPs associated with obesity
The carnitine O-octanoyltransferase gene (CROT) 
is located at chromosome 7q21.12 (NCBI Gene, https://
www.ncbi.nlm.nih.gov/gene) and is expressed in various 
tissues and organs including adipose tissue (The Human 
Protein Atlas, http://www.proteinatlas.org). The CROT 
protein is a member of the carnitine acyltransferase 
family and converts 4,8-dimethylnonanoyl-CoA to its 
corresponding carnitine ester. CROT activates lipid 
metabolism by promoting the β-oxidation of fatty acids 
[34]. We have now shown that rs7808249 (G/A) of CROT 
was related to obesity with the minor A allele representing 
a risk factor for this condition. This association of CROT 
with obesity may be attributable to the role of this gene 
in lipid metabolism, although the molecular mechanism 
remains unclear.
The tuberous sclerosis 1 gene (TSC1) is located 
at chromosome 9q34.13 (NCBI Gene) and is widely 
expressed including in adipose tissue (The Human Protein 
Atlas). TSC1 and TSC2 encode proteins that form a 
complex with each other that functions as an inhibitor of 
mechanistic target of rapamycin (mTOR) signaling [35, 
36]. Deletion, nonsense, or missense mutations of TSC1 
and TSC2 lead to loss of function of the TSC1-TSC2 
complex and constitutive activation of mTOR signaling. 
Such mutations of TSC1 or TSC2 cause tuberous sclerosis, 
a multisystem disorder associated with tumor formation 
in the brain, heart, lung, kidney, or eye [37, 38]. We have 
now shown that rs1076160 (A/G) of TSC1 was related to 
obesity, with the minor G allele being protective against 
this condition. The association of TSC1 with obesity 
might be attributable to the effect of this gene on protein 
synthesis and cell growth, although the underlying 
mechanism remains unknown.
The Ras and Rab interactor 3 gene (RIN3) is located 
at chromosome 14q32.12 (NCBI Gene) and is expressed in 
many tissues including adipose tissue (The Human Protein 
Table 6: Characteristics of the 6817 subjects in the EWAS for MetS
Characteristic MetS Controls P
No. of subjects 3998 2819
Age (years) 62.2 ± 11.5 54.1 ± 14.1 <0.0001
Sex (male/female, %) 60.0/40.0 44.7/55.3 <0.0001
BMI (kg/m2) 25.5 ± 3.6 21.0 ± 2.3 <0.0001
Waist circumference (cm) 87.0 ± 8.7 74.6 ± 6.2 <0.0001
Current or former smoker (%) 38.2 35.1 0.0111
Systolic blood pressure (mmHg) 141 ± 23 111 ± 11 <0.0001
Diastolic blood pressure (mmHg) 81 ± 14 68 ± 9 <0.0001
Fasting plasma glucose (mmol/L) 7.14 ± 2.93 4.97 ± 0.40 <0.0001
Blood hemoglobin A1c (%) 6.38 ± 1.41 5.41 ± 0.41 <0.0001
Serum triglycerides (mmol/L) 2.08 ± 1.32 0.89 ± 0.32 <0.0001
Serum HDL-cholesterol (mmol/L) 1.27 ± 0.37 1.81 ± 0.43 <0.0001
Serum LDL-cholesterol (mmol/L) 3.24 ± 0.93 3.00 ± 0.74 <0.0001
Serum creatinine (µmol/L) 83.5 ± 95.7 69.0 ± 64.0 <0.0001
Estimated GFR (mL min–1 1.73 m–2) 67.0 ± 22.1 77.7 ± 17.7 <0.0001
Serum uric acid (µmol/L) 350 ± 95 297 ± 83 <0.0001
Quantitative data are means ± SD and were compared between subjects with MetS and controls with the unpaired Student’s 
t test. Categorical data were compared between the two groups with Fisher’s exact test. Based on Bonferroni’s correction, a 
P value of <0.0033 (0.05/15) was considered statistically significant.
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Table 7: The 40 SNPs significantly (P < 1.20 × 10–6) associated with MetS in the EWAS
Gene dbSNP Nucleotide (amino acid) substitutiona
Chromosome: 
position
MAF (%) P (allele) AlleleOR
SLC4A5 rs10177833 A/C 2: 74230591 46.8 2.51 × 10–89 0.98
TAP2 rs2071544 A/G 6: 32838344 48.7 2.85 × 10–76 1.02
MYPN rs7916821 G/A (S707N) 10: 68174212 28.4 2.78 × 10–68 0.96
PSMD9 rs14259 A/G (E92G) 12: 121915890 46.3 8.72 × 10–63 1.00
ANKK1 rs1800497 G/A (E713K) 11: 113400106 37.1 9.27 × 10–61 1.02
ZNF700 rs75607624 T/G (F290C) 19: 11948884 3.7 1.32 × 10–53 0.97
PLEKHG1 rs17348890 A/G 6: 150839882 6.6 1.42 × 10–52 1.02
DEPDC7 rs34161108 G/A (A192T) 11: 33027795 6.2 3.94 × 10–51 1.02
ARHGEF28 rs536568 A/C 5: 73935841 45.8 9.67 × 10–44 0.99
IGSF22 rs7125943 C/T (V559M) 11: 18714400 18.6 7.53 × 10–40 1.03
PKD1L1 rs147417448 T/A (N1607K) 7: 47854920 0.4 1.87 × 10–35 0.83
TICRR rs79501973 G/A (V1373I) 15: 89624427 14.7 8.41 × 10–33 0.98
GBF1 rs143872476 T/C (M240T) 10: 102358118 0.2 2.59 × 10–31 1.85
ZNF804B rs1406503 C/G 7: 88931564 5.2 3.38 × 10–24 0.84
GON4L rs183379906 C/G (D1943E) 1: 155753217 0.3 6.69 × 10–23 1.00
rs962040 A/G 8: 15454368 30.1 5.33 × 10–21 0.98
rs365488 C/T 6: 29550181 48.8 7.69 × 10–21 1.01
CATSPERD rs73544757 T/C (V95A) 19: 5733863 0.3 2.11 × 10–20 0.96
rs1507493 A/G 4: 147108517 26.7 2.03 × 10–17 1.03
MCEE rs6748672 C/A (R104L) 2: 71124273 24.2 4.15 × 10–17 0.98
MAP1A rs3803335 G/A (R1185H) 15: 43525027 1.6 8.61 × 10–17 1.08
NXPE2 rs11215158 T/C (V103A) 11: 114698220 16.0 1.82 × 10–16 1.06
TRAT1 rs79029897 G/A (R179H) 3: 108853852 0.7 1.88 × 10–16 1.18
CCDC13 rs75893579 C/G (R153G) 3: 42752631 3.9 3.13 × 10–16 0.87
OR10W1 rs56302613 C/G (S245C) 11: 58267125 3.1 9.91 × 10–15 0.85
rs3135365 T/G 6: 32421478 18.9 2.71 × 10–14 0.93
ACAD10 rs192237004 A/G (Y578C) 12: 111744661 0.4 5.83 × 10–12 1.07
CSRNP3 rs1007732 G/T 2: 165602788 34.0 8.13 × 10–12 0.92
TEFM rs2433 T/C (I348V) 17: 30899210 18.1 4.20 × 10–8 1.03
B4GALNT2 rs7224888 T/C (C380R) 17: 49168801 3.5 6.94 × 10–8 1.05
BCAS3 rs2643103 G/A (S87N) 17: 60709264 12.5 8.49 × 10–8 1.02
PPARGC1B rs143268818 C/T 5: 149845772 0.6 8.50 × 10–8 0.84
rs56150213 G/A 17: 19761005 49.4 1.43 × 10–7 1.08
ZNF597 rs140727539 C/T (E315K) 16: 3436756 0.1 1.45 × 10–7 1.01
GPR179 rs201149338 C/G (Q1461E) 17: 38329188 3.1 1.51 × 10–7 0.89
TENM2 rs9313396 T/G 5: 168072827 50.0 2.45 × 10–7 1.02
PDP2 rs141108875 C/T (R473W) 16: 66885701 0.5 2.69 × 10–7 1.50
SLC15A1 rs12853441 C/A 13: 98725694 49.1 2.99 × 10–7 0.96
rs7350481 C/T 11: 116715567 27.7 7.43 × 10–7 1.21
rs9500989 C/G 6: 29802381 0.8 7.76 × 10–7 1.06
Allele frequencies were analyzed with Fisher’s exact test. aMajor allele/minor allele. OR, odds ratio.
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Atlas). The RIN3 protein is a member of the RIN family 
of Ras effectors [39] and activates Rab5 in human mast 
cells, leading to pathological conditions associated with 
mast cell–mediated chronic inflammation and mast cell 
hyperproliferation [40]. A GWAS showed that rs10498635 
of RIN3 was associated with Paget’s disease of bone 
[41]. Obesity is closely linked to chronic inflammation 
in adipose tissue [42–45]. We have now shown that 
rs8018360 (C/T) of RIN3 was related to obesity, with the 
minor T allele representing a risk factor for this condition. 
Although the mechanism underpinning this association 
remains to be determined, it may be attributable to an 
effect of RIN3 on inflammation in adipose tissue.
SNPs associated with MetS
We have now identified rs7350481 (C/T) at 
chromosomal region 11q23.3 as a new susceptibility 
locus for MetS in Japanese. Chromosome 11q23.3 
has previously been shown to be related to serum 
concentrations of triglycerides and HDL-cholesterol in 
Japanese and Mexican populations [32, 33]. In our study, 
rs7350481 was also significantly associated with the 
serum concentrations of triglycerides (P = 1.72 × 10–18) 
and of HDL-cholesterol in men (P = 0.0002). It was also 
related to the serum HDL-cholesterol concentration in 
women (P = 0.0054) and to the fasting plasma glucose 
level (P = 0.0060). The association of rs7350481 (C/T) at 
11q23.3 with MetS may thus be attributable to the effect 
of this SNP on lipid and glucose metabolism, although the 
underlying mechanism remains to be elucidated.
The ankyrin repeat and kinase domain containing 1 
gene (ANKK1) is located at chromosome 11q23.2 (NCBI 
Gene) and is expressed ubiquitously (The Human Protein 
Atlas). ANKK1 is closely linked to the D2 dopamine 
receptor gene, and rs1800497 of ANKK1 has previously 
Table 8: Relation of SNPs to MetS as determined by multivariable logistic regression analysis
SNP
Dominant Recessive Additive 1 Additive 2
P OR (95% CI) P
OR (95% 
CI) P
OR (95% 
CI) P
OR (95% 
CI)
rs1800497 G/A (E713K) 0.8813 0.0227
1.19 (1.02–
1.38) 0.5289 0.0627
rs1406503 C/G 0.0212 0.82 
(0.69–0.97)
0.0597 0.0477 0.84 (0.70–0.99) 0.0545
rs1007732 G/T 0.0344 0.89 (0.81–0.99) 0.1245 0.0861 0.0435
0.84 (0.71–
0.99)
rs56150213 G/A 0.0094 1.17 (1.04–1.31) 0.4890 0.0121
1.17 
(1.04–1.33) 0.0478
1.16 (1.00–
1.34)
rs7350481 C/T 7.99 × 10–5
1.23 
(1.11–1.36)
0.0018 1.35 (1.12–
1.63)
0.0018 1.19 (1.07–1.32) 0.0001
1.45 (1.20–
1.77)
Multivariable logistic regression analysis was performed with adjustment for age and sex. Based on Bonferroni’s correction, 
P values of <3.13 × 10–4 (0.05/160) were considered statistically significant and are shown in bold.
Table 9: Relation of SNPs identified in the present study to each component of MetS
SNP Waist 
circumference
Serum 
triglycerides
Serum HDL-
cholesterol Systolic 
BP
Diastolic 
BP
Fasting 
plasma glucose
Men Women Men Women
rs1800497 G/A (E713K) 0.6493 0.0334 0.0662 0.0142 0.3710 0.0874 0.4210 0.0667
rs1406503 C/G 0.6225 0.7892 0.4958 0.3470 0.9441 0.3309 0.3962 0.4527
rs1007732 G/T 0.9507 0.0375 0.2333 0.0145 0.0321 0.1330 0.1602 0.3483
rs56150213 G/A 0.9135 0.1495 0.1220 0.5452 0.8970 0.7663 0.4566 0.4820
rs7350481 C/T 0.9403 0.7694 1.72 × 10–18 0.0002 0.0054 0.1548 0.3894 0.0060
Data are P values for comparisons among genotypes by one-way ANOVA. Based on Bonferroni’s correction, P values of 
<0.0013 (0.05/40) were considered statistically significant and are shown in bold. BP, blood pressure.
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been associated with both addictive disorders [46] and 
obesity [47, 48]. Moreover, obese individuals manifest 
fewer D2 receptors in the striatum compared with lean 
ones [48, 49]. We have now shown that rs1800497 [G/A 
(E713K)] of ANKK1 was related to MetS, with the minor 
A allele representing a risk factor for this condition. This 
association of ANKK1 with MetS may be attributable to an 
effect of this gene on obesity.
The zinc finger protein 804B gene (ZNF804B) 
is located at chromosome 7q21.13 (NCBI Gene) and is 
expressed at a high level in the thyroid gland (The Human 
Protein Atlas). The rs1406503 (C/G) SNP of ZNF804B has 
previously been shown to be related to BMI in Filipino 
women [31]. We have shown that this SNP was related to 
MetS in Japanese, with the minor G allele being protective 
against this condition. It is possible that the association 
ZNF804B with MetS is attributable to the effect of this 
gene on BMI.
The cysteine and serine rich nuclear protein 3 gene 
(CSRNP3) is located at chromosome 2q24.3 (NCBI Gene) 
and is expressed ubiquitously (The Human Protein Atlas). 
The three members of the CSRNP family of nuclear 
proteins (CSRNP1, -2, and -3) share conserved regions 
including cysteine- and serine-rich regions and a basic 
domain, possess a transcriptional activation domain, and 
bind to the DNA sequence motif AGAGTG [50]. We 
have now shown that rs1007732 (G/T) of CSRNP3 was 
related to MetS, with the minor T allele being protective 
against this condition, although the molecular mechanism 
underlying this association remains unclear.
Chromosome 17p11.2 has been shown to be related 
to longevity [51] and glomerular filtration rate [52], but it 
has not been previously found to be related to MetS. We 
have now shown that rs56150213 (G/A) at 17p11.2 was 
related to MetS, with the minor A allele representing a risk 
factor for this condition, although the functional relevance 
of this association remains unknown.
General considerations
In a previous GWAS [15] and meta-analyses of 
GWASs [16, 17] for BMI in East Asian populations, 
the MAF and effect size (explained variance in BMI) of 
identified SNPs ranged from 3% to 50% and from 0.02% 
to 0.20%, respectively. In the case of SNPs of FTO, 
the MAF and effect size of rs12149832 were 20% and 
0.20%, respectively [15]; those of rs17817449 were 17% 
and 0.18%, respectively [16]; and those of rs1558902 
were 15% and 0.15%, respectively [17]. In our study, we 
identified six SNPs associated with BMI, with the MAF 
and effect size (percentage difference in BMI among 
genotypes) of rs633715 and rs543874 at 1q25 as well 
as of rs1421085, rs1558902, rs8050136, and rs9939609 
of FTO being 22.0% and 1.7%, 21.9% and 1.7%, 19.1% 
and 2.1%, 19.1% and 2.1%, 19.2% and 2.1%, and 19.3% 
and 2.1%, respectively. These SNPs were thus common 
variants with a moderate effect size. For SNPs related to 
obesity in the present study, the MAF and allele odds ratio 
for obesity of rs7808249, rs1076160, and rs8018360 were 
32.0% and 1.06, 45.9% and 0.95, and 19.9% and 1.04, 
respectively. These SNPs were thus common variants 
with a small effect size. The MAF and allele odds ratio 
for MetS for rs7350481 identified in the present study 
were 27.7% and 1.21, respectively, revealing this SNP 
to be a common variant with a moderate effect size. For 
the four additional SNPs related to MetS in our study, 
the MAF and allele odds ratio for MetS of rs1800497, 
rs1406503, rs1007732, and rs56150213 were 37.1% and 
1.02, 5.2% and 0.84, 34.0% and 0.92, and 49.4% and 1.08, 
respectively. These SNPs were thus common variants with 
a small effect size.
There are several limitations to the present study. 
(i) There were significant differences in age and sex 
between subjects with obesity or MetS and corresponding 
controls, which may be caused by selection bias of study 
subjects. (ii) Given that our results were not replicated, 
they will require validation in other populations. (iii) It 
is possible that SNPs identified in the present study are 
in linkage disequilibrium with other polymorphisms in 
nearby genes that are actually responsible for the observed 
associations. (iv) Three SNPs associated with obesity 
were not significantly related to BMI, and four SNPs 
associated with MetS were not related to components of 
this syndrome. The discrepancy in the obesity study might 
be attributable to substantial percentages of subjects with 
BMI close to 25 kg/m2. The discrepancy in the MetS study 
might be attributable to the effects of medical treatment 
for dyslipidemia, hypertension or diabetes mellitus 
in most subjects with MetS. A lack of relation to waist 
circumference might be due to substantial percentages 
of subjects with waist circumference close to cut-off 
values. (v) Information of treatment such as medication 
and duration of treatment was not available in the present 
study. (vi) The functional relevance of the identified SNPs 
to BMI or the pathogenesis of obesity or MetS remains to 
be determined.
In conclusion, we have identified rs7350481 (C/T) 
at 11q23.3 as a novel susceptibility locus for MetS. We 
also identified three genes (CROT, TSC1, RIN3) as new 
candidate susceptibility loci for obesity as well as three 
genes (ANKK1, ZNF804B, CSRNP3) and chromosome 
17p11.2 as new candidate loci for MetS. Examination of 
genotypes for the identified SNPs may prove informative 
for assessment of the genetic risk for obesity or MetS in 
Japanese.
MATERIALS AND METHODS
Study subjects
For the BMI, obesity, and MetS studies, 12,890, 
12,968, or 6817 subjects, respectively, were examined. 
The subjects were recruited from individuals as previously 
described [53].
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On the basis of the recent recognition of a need 
to revise BMI criteria for obesity in Japanese and other 
Asian populations [54], obesity was defined as a BMI 
of ≥25 kg/m2. According to this definition, we examined 
3954 subjects with obesity and 9014 controls for the 
obesity study, with the control individuals having a BMI 
of <25 kg/m2. Individuals with obesity associated with 
single gene disorders or with metabolic or endocrinologic 
diseases were excluded from the study, as were those 
taking medications that may cause secondary obesity. 
These subjects were largely the same as those for the BMI 
study.
Diagnosis of MetS was based on a modified 
version of the definition proposed by the International 
Diabetes Federation Task Force on Epidemiology and 
Prevention; National Heart, Lung, and Blood Institute; 
American Heart Association; World Heart Federation; 
International Atherosclerosis Society; and International 
Association for the Study of Obesity [18]. We used 
cutoff values for waist circumference of ≥90 cm in men 
or ≥80 cm in women on the basis of a recommendation 
of the International Diabetes Association [18]. A total of 
3998 subjects with MetS thus had three or more of the 
following five components: (i) a waist circumference 
of ≥90 cm for men or ≥80 cm for women; (ii) a serum 
triglyceride concentration of ≥1.65 mmol/L (150 mg/
dL) or drug treatment for elevated triglycerides; (iii) a 
serum HDL-cholesterol concentration of <1.04 mmol/L 
(40 mg/dL) for men or <1.30 mmol/L (50 mg/dL) for 
women; (iv) a systolic blood pressure of ≥130 mmHg, 
diastolic blood pressure of ≥85 mmHg, or drug treatment 
for hypertension; and (v) a fasting plasma glucose 
level of ≥5.50 mmol/L (100 mg/dL) or drug treatment 
for elevated glucose. History of obesity, dyslipidemia, 
hypertension, or diabetes mellitus was evaluated with a 
detailed questionnaire. The control subjects comprised 
2819 individuals who had none of the five components of 
MetS. Autopsy cases were excluded from controls for both 
the obesity and MetS studies.
The study protocol complied with the Declaration 
of Helsinki and was approved by the Committees on the 
Ethics of Human Research of Mie University Graduate 
School of Medicine, Hirosaki University Graduate School 
of Medicine, Tokyo Metropolitan Institute of Gerontology, 
and participating hospitals. Written informed consent was 
obtained from each participant or families of the deceased 
subjects.
EWASs for BMI, obesity, and MetS
Methods for collection and extraction of genomic 
DNA samples were described previously [53]. The EWASs 
were performed with the use of the HumanExome-12 v1.1 
or v1.2 DNA Analysis BeadChip or Infinium Exome-24 
v1.0 BeadChip (Illumina, San Diego, CA, USA). Detailed 
information of these exome arrays and methods of quality 
control were described previously [53]. Totals of 41,327 
or 41,675 SNPs passed quality control for the BMI and 
obesity studies and for the MetS study, respectively, and 
were subjected to analysis.
Statistical analysis
For analysis of the characteristics of study 
subjects, quantitative data were compared between 
subjects with obesity or MetS and controls with 
the unpaired Student’s t test. Categorical data were 
compared between two groups with Fisher’s exact 
test. The relation of genotypes of SNPs to BMI in the 
EWAS was examined by linear regression analysis. 
Allele frequencies were estimated by the gene counting 
method, and Fisher’s exact test was used to identify 
departure from Hardy-Weinberg equilibrium. The 
relation of allele frequencies of SNPs to obesity or 
MetS in the EWASs was examined with Fisher’s 
exact test. To compensate for multiple comparisons of 
genotypes or allele frequencies with BMI, obesity, or 
MetS, we applied Bonferroni’s correction for statistical 
significance of association. Given that 41,327 or 41,675 
SNPs were analyzed in the BMI or obesity and the 
MetS studies, respectively, the significance level was 
set at P < 1.21 × 10–6 (0.05/41,327) or P < 1.20 × 10–6 
(0.05/41,657), respectively. Quantile-quantile plots for 
P values of genotypes in the EWAS for BMI or for those 
of allele frequencies in the EWASs for obesity or MetS 
are shown in Supplementary Figure 2. The inflation 
factor (λ) was 1.03 for BMI, 1.22 for obesity, and 1.13 
for MetS. Multivariable logistic regression analysis was 
performed with obesity or MetS as a dependent variable 
and independent variables including age, sex (0, woman; 
1, man), and genotype of each SNP. A detailed method 
of analysis was described previously [53]. The relation 
of genotypes of SNPs identified in the EWASs to BMI 
or the five components of MetS was examined by one-
way ANOVA. Bonferroni’s correction was also applied 
to other statistical analysis as indicated. Statistical 
tests were performed with JMP Genomics version 6.0 
software (SAS Institute, Cary, NC, USA).
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